Anvisa Prohibits Batches of Medicine to Treat Cancer
19 Articles
19 Articles
CartaCapital
The suspicion of the National Surveillance Agency is that pharmaceuticals are falsified
The National Agency for Health Surveillance (Anvisa) has determined the seizure and prohibition of the marketing, distribution and use of a fake batch of the medicine Dysport (botulinic toxin). The fake batch is number 025155. The decision was motivated by a statement from the company holding the registry (Beaufour Ipsen Pharmaceutical Ltd.), which identified counterfeit units in circulation. According to the agency, the fake product had a diver…
The registry company identified two batches suspected of falsification and notified the health surveillance body
Forbes, the world's most well-conceived business and economic magazine. Suspected of being counterfeit products The post Anvisa Prohibited Lots of Medicine to Treat Cancer apareceu primeiro em Forbes Brasil.
The National Agency of Health Surveillance (Anvisa) has lit the warning signal for clinics, hospitals, pharmacies and cancer patients throughout the country. The body has determined the immediate arrest and the prohibition of the movement of specific batches of the drug Keytruda (pembrolizumab) 100 mg/4 mL, an immunotherapy widely used in the treatment of various types of cancer. [...] Read more in Anvisa orders to seize batches of drug against …
The National Agency for Health Surveillance (Anvisa) determined the seizure of batch 025155 of the medicinal product Dysport, a neuromodulator based on botulinum toxin. The decision was published on Monday (19) in the Official Journal of the Union. In a note, Anvisa informed that the owner of the registration of the product, Beaufour Ipsen Pharmaceutical Ltda., identified units of [...]
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
